De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Jeevan Scientific Technology Inkomsten in het verleden
Verleden criteriumcontroles 0/6
Jeevan Scientific Technology has been growing earnings at an average annual rate of 5.4%, while the Life Sciences industry saw earnings growing at 20.2% annually. Revenues have been growing at an average rate of 8% per year.
Belangrijke informatie
5.4%
Groei van de winst
5.6%
Groei van de winst per aandeel
| Life Sciences Groei van de industrie | 11.2% |
| Inkomstengroei | 8.0% |
| Rendement op eigen vermogen | -1.7% |
| Nettomarge | -1.7% |
| Laatste winstupdate | 30 Jun 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Opbrengsten en kosten
Hoe Jeevan Scientific Technology geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 421 | -7 | 162 | 0 |
| 31 Mar 24 | 397 | -13 | 159 | 0 |
| 31 Dec 23 | 365 | -29 | 161 | 0 |
| 30 Sep 23 | 363 | -23 | 164 | 0 |
| 30 Jun 23 | 362 | -29 | 162 | 0 |
| 31 Mar 23 | 362 | -30 | 155 | 0 |
| 31 Dec 22 | 402 | -1 | 191 | 0 |
| 30 Sep 22 | 512 | 41 | 201 | 0 |
| 30 Jun 22 | 619 | 90 | 191 | 0 |
| 31 Mar 22 | 685 | 119 | 225 | 0 |
| 31 Dec 21 | 703 | 152 | 191 | 0 |
| 30 Sep 21 | 651 | 166 | 173 | 0 |
| 30 Jun 21 | 596 | 156 | 144 | 0 |
| 31 Mar 21 | 475 | 117 | 140 | 0 |
| 31 Dec 20 | 411 | 24 | 206 | 0 |
| 30 Sep 20 | 337 | -29 | 203 | 0 |
| 30 Jun 20 | 267 | -71 | 108 | 0 |
| 31 Mar 20 | 249 | -86 | 192 | 0 |
| 31 Dec 19 | 212 | -46 | 108 | 0 |
| 30 Sep 19 | 208 | -42 | 102 | 0 |
| 30 Jun 19 | 232 | -14 | 87 | 0 |
| 31 Mar 19 | 261 | 11 | 97 | 0 |
| 31 Dec 18 | 261 | 25 | 89 | 0 |
| 30 Sep 18 | 239 | 18 | 83 | 0 |
| 30 Jun 18 | 213 | 5 | 76 | 0 |
| 31 Mar 18 | 204 | 1 | 69 | 0 |
| 31 Dec 17 | 214 | 7 | 59 | 0 |
| 30 Sep 17 | 200 | 8 | 47 | 0 |
| 30 Jun 17 | 189 | 8 | 27 | 0 |
| 31 Mar 17 | 182 | 9 | 31 | 0 |
| 31 Dec 16 | 167 | -7 | 58 | 0 |
| 30 Sep 16 | 171 | -7 | 53 | 0 |
| 30 Jun 16 | 175 | -3 | 0 | 0 |
| 01 Apr 16 | 174 | 0 | 44 | 0 |
| 31 Dec 15 | 167 | 15 | 19 | 0 |
| 30 Sep 15 | 153 | 15 | 19 | 0 |
| 30 Jun 15 | 147 | 18 | 0 | 0 |
| 31 Mar 15 | 134 | 14 | 19 | 0 |
| 31 Dec 14 | 141 | 22 | 12 | 0 |
| 30 Sep 14 | 131 | 21 | 12 | 0 |
| 30 Jun 14 | 94 | 8 | 12 | 0 |
| 31 Mar 14 | 64 | 2 | 16 | 0 |
| 31 Dec 13 | 28 | -20 | 23 | 0 |
Kwaliteitswinsten: 538837 is currently unprofitable.
Groeiende winstmarge: 538837 is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: 538837 is unprofitable, but has reduced losses over the past 5 years at a rate of 5.4% per year.
Versnelling van de groei: Unable to compare 538837's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: 538837 is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (13.3%).
Rendement op eigen vermogen
Hoge ROE: 538837 has a negative Return on Equity (-1.66%), as it is currently unprofitable.